Cytokines in Chronic Pancreatitis and Pancreatic Cancer

  • Maksuda Shamsutdinova Clinic of Internal Medicine II, University Hospital, Freiburg, Germany.
  • R. Timme Department of Internal Medicine, Haematology, Tashkent Medical Academy, Republic of Uzbekistan
  • Sh. Zakirkhodjaev Department of Internal Medicine, Haematology, Tashkent Medical Academy, Republic of Uzbekistan
  • G. Sadriddinova Clinic of Internal Medicine II, University Hospital, Freiburg, Germany.
Keywords: Chronic pancreatitis, Cytokines, Pancreas Carcinoma, Pathogenesis.

Abstract

Aims: Blood levels of pro- and anti-inflammatory cytokines were measured in 40 patients with chronic pancreatitis (CP), and pancreatic cancer (PC) as compared to healthy controls.

Methods: With respect to the blood levels of pro- and anti-inflammatory cytokines in the 40 patients with chronic pancreatitis (CP), and pancreatic cancer (PC), there was a significant increase of interleukin-2 receptor (IL-2R) and interleukin-6 (IL-6) as compared to healthy controls.

Result. Clinical and laboratory analyses revealed an enlargement of the pancreas in 32 (80%), and of the spleen in 3 (7%) patients, respectively. Elevated bilirubin was present in 17 patients (41%), significantly elevated lipase, gamma-glutamyl trans peptidase and alkaline phosphatase activities were found in 24 (62%) patients.  ALT and AST activities were significantly elevated in 20 (50%), moderately elevated (3-5 xULN) in 6(15%) patients and slightly elevated (1.5-3 x ULN) in 14 (35%) patients.  Serum albumin levels were reduced in 21 (51%) patients. The tumor markers CA 19-9 was elevated in 15 (38%) patients with a tumor in the head of the pancreas that was confirmed by computer tomography.

Conclusion. The results indicate that cytokines are activated in patients with CP and PC respectively. This activation is accompanied by an increased levels of pro-inflammatory cytokines IL-2R, IL-6, TNF-αand INF-y, which closely correlate with the major pathological clinical and laboratory parameters in these patients. 

 

Downloads

Download data is not yet available.

References

1. Tasnim Ara, T. Declerck YA (2010).Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 46:1223-1231.
2. Talukdar R, Tandon RK (2008). Pancreatic stellate cells: New target in the treatment of chronic pancreatitis. J Gastroenterol Hepatol 23:34-41.
3. Guo Y, Xu F, Lu T, Duan Z, Zhang Z (2012).Interleukin-6 signalling pathway in targeted therapy for cancer. Cancer Treat Rev 38:904-10.
4. Schultz NA, Christensen IJ, Werner J, Giese N, Jensen BV, et al(2013).Diagnostic and prognostic impact of circulatingYKL-40, IL-6, and CA 19-9 in patients with pancreatic cancer. PLoS One 8: e67059.
5. Talukdar R, Saikia N, Singal DK, Tandon R (2006). Chronic pancreatitis: Evolving paradigms. Pancreatology. 6:440-9.
2.
6. Matsuo Y, Takeyama H, Guha S (2012) Cytokine network: new targeted therapy for pancreatic cancer. Curr Pharm Des 18: 2416–2419.
7. Zhang Y, Yan W, Collins MA, Bednar F, Rakshit S et al (2013). Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signalling activation and oxidative stress resistance. Cancer Res 73: 6359-6374.
8. Apte M, Phillips P, Fahmy R (2008). Alcohol directly stimulates rat pancreatic stellate cells. Gastroenterology 118:780-94.
Published
2016-03-20
How to Cite
1.
Shamsutdinova M, Timme R, Zakirkhodjaev S, Sadriddinova G. Cytokines in Chronic Pancreatitis and Pancreatic Cancer. Int Arch BioMed Clin Res [Internet]. 2016Mar.20 [cited 2020Dec.3];2(1):9-13. Available from: https://iabcr.org/index.php/iabcr/article/view/223
Section
ORIGINAL ARTICLES ~ General Surgery